Journal
CELLULAR & MOLECULAR IMMUNOLOGY
Volume 13, Issue 1, Pages 57-64Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/cmi.2014.114
Keywords
cancer prevention; cancer treatment; CD107a; cytotoxicity; dimethyl fumarate; Granzyme B; monomethyl fumarate; natural killer cells; NKp46
Categories
Funding
- University of Oslo
- Biogen-Idec Global, Inc.
- Vivi Irene Hansens Funds for Systemic Lupus Erythematosus
Ask authors/readers for more resources
Dimethyl fumarate (DMF) is a new drug used to treat multiple sclerosis (MS) patients. Here, we examined the effects of DMF and the DMF metabolite monomethyl fumarate (MMF) on various activities of natural killer (NK) cells. We demonstrated that MMF augments the primary CD56(+), but not CD56(-), NK cell lysis of K562 and RAJI tumor cells. MMF induced NKp46 expression on the surface of CD56(+), but not CD56(-), NK cells after incubation for 24 h. This effect was closely correlated with the upregulation of CD107a expression on the surface of CD56(+) NK cells and the induction of Granzyme B release from these cells through this metabolite. An anti-NKp46 antibody inhibited the MMF-induced upregulation of CD107a and the lysis of tumor cells through CD56(+) NK cells. Thus, these results are the first to show that MMF augments CD56(+) NK cell lysis of tumor target cells, an effect mediated through NKp46. This novel effect suggests the use of MMF for therapeutic and/or preventive protocols in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available